Tech Company Financing Transactions
Hillhurst Biopharmaceuticals Funding Round
Friedman BioVentures and private investors joined a Seed funding round for Hillhurst Biopharmaceuticals. The funding round was recorded on 12/20/2023.
Transaction Overview
Company Name
Announced On
12/20/2023
Transaction Type
Amount
Unknown
Round
Seed
Investors
Friedman BioVentures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its Phase 2a clinical studies in sickle cell disease and in a second clinical indication.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11175 Flintkote Ave B
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
We founded Hillhurst to liberate Sickle Cell Disease patients from the horrendous, recurrent, lifelong severe painful episodes and accompanying organ injury of this life limiting disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Gomperts
Founder
Edward Gomperts
Browse more venture capital transactions:
Prev: 12/20/2023: Lassen Therapeutics venture capital transaction
Next: 12/21/2023: Academic Labs venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs